News and Trends 23 Jul 2018 Sangamo Acquires French Biotech to Develop CAR-T Therapies for Autoimmune Disease Sangamo Therapeutics has acquired TxCell with a view to utilizing its CAR-T technology to prevent organ transplant rejections and treat autoimmune disease. Sangamo, based in California, is known for bringing the first in-vivo gene therapy to the market. The company entered into an agreement to purchase TxCell for €72M. Sangamo plans to combine its zinc […] July 23, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 21 Jul 2018 Somewhere in Between: Exploring Art and Science Collaborations The latest art and science exhibition at the Wellcome Collection, Somewhere in Between, explores ideas about cattle farming, multisensory synaesthesia, sexual health and virus transmission, and the human capacity to breathe. In an unprecedented level of collaboration, the exhibition is comprised of four art-science projects stemming from projects funded by the Wellcome Trust with the […] July 21, 2018 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2018 Belgian Biotech Completes First Trial with New Drug for Diabetic Macular Edema Belgian biotech ThromboGenics has conducted the first clinical trial of an antibody to treat one of the world’s leading causes of vision loss. Results from the Phase I/II trial demonstrate the safety and tolerability of a new kind of antibody treatment for diabetic macular edema. The trial focused on injecting the THR-317 antibody, which is directed against […] July 20, 2018 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2018 German Private Equity Firm Raises €90M for Life Sciences and Medtech SHS has raised €90M in the first closing of its fifth fund dedicated to companies in life sciences and medtech. SHS, based in Tübingen, is aiming to raise a total of €150M for its fifth fund. In this first closing, around half of the €90M raised came from existing investors including professional pension insurers and family […] July 20, 2018 - 1 minutemin - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 19 Jul 2018 Kite Partners with Dutch Biotech to Develop a New Form of CAR-T Therapy Kite will support Gadeta in the development of a new type of CAR-T therapy that could be more effective in solid tumors. Approved just last year, CAR-T cell therapy is offering hope to patients with severe forms of blood cancer. The developer of one of only two CAR-T therapies currently in the market, Kite, has […] July 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Jul 2018 Gene Therapy Could Prevent Deadly Brain Disease An international research team used gene therapy to prevent Gaucher disease, a potentially deadly neurodegenerative condition, in mice. The approach could eventually be used to treat human diseases in the womb. A research team from the UK and Singapore showed that a neurodegenerative condition called Gaucher disease, which can be fatal, can be prevented in […] July 17, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jul 2018 CRISPR-Cas9 Shown to Cause Previously Unseen DNA Damage Researchers at the Wellcome Trust Sanger Institute in the UK have found that gene editing with CRISPR-Cas9 can cause significantly more off-target damage to the DNA than previously thought. Published today in Nature Biotechnology, the study is the first to look at unexpected DNA changes caused by CRISPR across large regions of the genome. […] July 16, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jul 2018 Series A Boost for Swedish Biotech’s Sickle Cell Disease Treatment Modus Therapeutics closed SEK 140M (€13.5M) in Series A financing to complete a Phase II study testing its sickle cell disease drug and to prepare for further clinical trials. The financing round was led by HealthCap, a European venture capital firm focused on life science investments, which will contribute SEK 60M (€5.8M). The remaining funds […] July 16, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 13 Jul 2018 French Biotech Raises €12.5M for Antibiotic Booster Drugs French-biotech Antabio closed €12.5M at series A to fund its pipeline of antibiotic booster drugs that should help in the global fight against antimicrobial resistance. After raising €7.3M last year, Antabio extended its Series A financing round with €5.2M of additional funding raised from private investors. The French biotech will use the funding to continue […] July 13, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2018 Collaboration Worth Over €1Bn Could Give Rise to New Cancer Immunotherapies Genmab is partnering with the German company Immatics to develop immunotherapies directed against three cancer targets. Genmab has offered Immatics, based in Tuebingen, Germany, an upfront payment of $54M (€46M) in addition to milestone payments worth up to $550M (€470M) for each product. Genmab has a market cap of €60Bn ($70Bn). The funding will be […] July 12, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2018 Radioactive Nanoparticle Could Improve Cancer Diagnoses Isotopia Molecular Imaging, an Israeli company, is developing a radioactive marker made of gold nanoparticles to detect cancer more accurately than with current diagnostic tools. PET and CT scans are two types of X-ray tests that use small quantities of radioactive materials, called contrast agents, to help visualize and assess organ and tissue function. These […] July 11, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2018 Gene Therapy for Retinitis Pigmentosa Tested in Humans for the First Time French biotech Horama has treated the first patients with a gene therapy for retinitis pigmentosa that could prevent the progressive loss of vision caused by this genetic condition. A Phase I/II trial with Horama’s gene therapy for retinitis pigmentosa is running at the Nantes University Hospital. The therapy is aimed at fixing genetic defects in a […] July 11, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email